title: [Combined treatment of BPS with tamsulosin and finasteride : Literature review and prescription data].
abstract: Combined therapy of benign prostatic syndrome (BPS) with α1-blockers and 5α-reductase (5AR)-inhibitors is recommended according to two leading studies on doxazosin/finasteride and tamsulosin/dutasteride for all 10 in Germany possible combinations (five α1-blockers and two 5AR inhibitors). Because tamsulosin and finasteride predominate in the treatment of BPS in Germany, the role of the combination tamsulosin/finasteride and its scientific basis from clinical studies has been investigated. A pharmacoepidemiological extrapolation from receipts of pharmacy data centres showed a strong increase of the combination tamsulosin/finasteride since 2003. As a free combination, tamsulosin/finasteride beside the fixed combination tamsulosin/dutasteride accounts to about 50% of all α1-blocker/5AR-inhibitor combinations today. Clinical studies on tamsulosin/finasteride have been published including controlled studies of the combination and both monotherapies. The results of improvement of lower urinary tract symptoms (LUTS), maximum urinary flow rate (Qmax), prostate volume (PV) and prostate-specific antigen (PSA) as well as adverse events and drug safety are in agreement with the leading studies. However, results due to chance cannot be excluded because of deficiencies in study design. A reliable comparison of the risk of progression between tamsulosin/finasteride and both monotherapies is lacking completely. Because of the great coherence and continuous evaluation of available data of all combinations, and with the established strong class effect of monotherapies, a continuation of the therapeutic practice with the combination tamsulosin/finasteride is possible.
authors.affiliation: Ev. Krankenhaus, Virchowstr. 20, 46047, Oberhausen, Deutschland. klaus.hoefner@eko.de.
authors.forename: K
authors.initials: K
authors.lastname: Höfner
authors.affiliation: Med.-wiss. Abteilung, Aristo Pharma GmbH, Berlin, Deutschland.
authors.forename: S
authors.initials: S
authors.lastname: Ulrich
authors.affiliation: PAN Klinik am Neumarkt, Köln, Deutschland.
authors.forename: R
authors.initials: R
authors.lastname: Berges
mesh_terms: D015984:Causality; D015897:Comorbidity; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004338:Drug Combinations; D011307:Drug Prescriptions / Q000706:statistics & numerical data*; D018120:Finasteride / Q000008:administration & dosage*; D006801:Humans; D015994:Incidence; D059411:Lower Urinary Tract Symptoms / Q000453:epidemiology* / Q000517:prevention & control*; D008297:Male; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000453:epidemiology*; D013449:Sulfonamides / Q000008:administration & dosage*; D000077409:Tamsulosin; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; D013449:Sulfonamides; D018120:Finasteride; D000077409:Tamsulosin
keywords: 5-alpha reductase inhibitors; Adrenergic alpha-1 receptor blockers; Finasteride; Prostatic hyperplasia, benign; Tamsulosin